Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma

NCT00630409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Gemcitabine
DRUG: Doxil

Sponsor

University of Pittsburgh